ABL 104
Alternative Names: ABL-104; YH-32364Latest Information Update: 23 May 2025
At a glance
- Originator ABL Bio
- Developer ABL Bio; Yuhan
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action CD137 antigen agonists; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastric cancer
Most Recent Events
- 16 May 2025 Yuhan Corporation plans a phase I/II trial for Solid tumours (Late-stage disease, Metastatic disease) in South Korea (IV, Infusion) in June 2025 (NCT06975410)
- 25 Apr 2025 Pharmacodynamics and adverse events data from a preclinical study in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 04 Oct 2024 ABL Bio plans a clinical trial for Gastric cancer